Drug details

Evkeeza (evinacumab-dgn for injection)

type of Lipid-Lowering Agents, Other

Evkeeza (evinacumab-dgnb) is an ANGPTL3 (angiopoietin-like 3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• nausea,
• itching,
• rash,
• fever,
• lightheadedness,
• wheezing,
• muscle weakness
• stuffy nose, and

The following drugs are related to Evkeeza, either as a replacement or used together:

• Praluent (alirocumab for solution for subcutaneous injection)
• Altocor (lovastatin extended-release tablets)
• Altoprev (lovastatin extended-release tablets)
• Caduet (amlodipine besylate, atorvastatin calcium)
• Lipitor (atorvastatin calcium)
• Welchol (colesevelam hcl)
• Repatha (evolocumab injection, for subcutaneous injection)
• Ezallor (rosuvastatin calcium tablets)
• Vytorin (ezetimibe and simvastatin)
• Fibricor (fenofibric acid)
• Trilipix (fenofibric acid capsules)
• FloLipid (simvastatin oral suspension)
• Juxtapid (lomitapide capsules)
• Livalo (pitavastatin)
• Niaspan (niacin)
• Zypitamag (pitavastatin tablets for oral use)
• Pravachol (pravastatin sodium)
• Zocor (simvastatin)